Pharmabiz2d
Glaukos announces positive clinical updates for its iDose sustained-release procedural pharmaceutical platform
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced several ...
Pharmabiz2d
Vistagen reports positive results from exploratory phase 2A study of PH284 in cancer cachexia
Vistagen, a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, announced positive results from an exploratory phase 2A study of PH284 in cancer ...
Pharmabiz2d
ACT commits Rs. 8.33 crore to the future of rural healthcare in India with Khushi Baby & Medoplus
ACT, an Indian venture philanthropy platform, has committed Rs. 8.33 crore in catalytic grants to Khushi Baby and Medoplus; social startups that are pioneering tech-first solutions to revolutionise ...
Pharmabiz4d
Novartis Entresto US patent upheld by US Court of Appeals
Novartis, an innovative medicines company, announced that the company is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that ...
Pharmabiz5d
Pfizer’s sasanlimab in combo with BCG improves EFS in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer
Pfizer Inc. announced positive topline results from its pivotal phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette ...
Pharmabiz6d
Allowing separate timelines for large units and MSMES may create two categories of manufacturing facilities: Experts
Allowing separate timelines for the large scale manufacturers and micro, small and medium enterprises (MSMEs) who have turnover of less than Rs. 250 crore in pharma sector to comply with the ...
Pharmabiz2d
Olfactive Biosolutions granted third dual GLP-1/GIP patent in US to repurpose food molecules for weight management and blood sugar regulation
Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted a third patent for inducing the secretion of GLP-1 and GIP, in US patent US 12,171,727 B1 ...
Pharmabiz2d
Acadia Pharma seeks European marketing approval for trofinetide for the treatment of Rett syndrome
Acadia Pharmaceuticals Inc., a company is advancing breakthroughs in neuroscience to elevate life, announced that the company has submitted a Marketing Authorization Application (MAA) to the European ...
Pharmabiz2d
Signet begins patient dosing in phase I trial in China for SIGX1094 to treat diffuse gastric cancer and other advanced solid tumours
Signet Therapeutics (Signet), a clinical-stage biotech company leveraging organoids and AI to develop first-in-class cancer therapies, announced that the first patient has been dosed in the phase I ...
Pharmabiz3d
Health Canada approves MedMira’s Reveal G4 Rapid HIV-1/2 test for point-of-care use
MedMira Inc. (MedMira) announced that it has received the approval from Health Canada for its Reveal Rapid G4 HIV-1/2 Test (Reveal HIV test) for Point-of-Care (POC) use. The Reveal HIV rapid test has ...
Pharmabiz2d
Pasithea Therapeutics opens European clinical trial sites and completes initial dosing of cohort 4
Pasithea Therapeutics Corp., a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other ...
Pharmabiz6d
Exporters concerned over delay in getting relief under Section 43B(h) of IT Act
India’s pharmaceutical exporters are on edge as they await a decisive response from the government regarding their long pending appeal for relief under the restrictive payment conditions of Section ...